|
|
Blood, 1 February 2004, Vol. 103, No. 3, pp. 1158-1165.
Prepublished online as a Blood First Edition Paper on October 2, 2003; DOI 10.1182/blood-2003-04-1098.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation
Wayne R. Godfrey,
Mark R. Krampf,
Patricia A. Taylor, and
Bruce R. Blazar
From the Departments of Pediatrics and Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, MN.
Eliminating alloreactive cells from T-cell populations would enable the transfer of immune function to patients who receive stem cell transplants. However, high-efficiency depletion has proved difficult to achieve. We sought to develop ex vivo approaches for the maximal depletion of alloreactive CD4+ T cells. Using a flow cytometric cell sorting approach after mixed lymphocyte reaction (MLR) culture, we have found that sorted CFSEbright (5-(and-6)-carboxyfluorescein diacetate succinmidyl ester) (nondivided) and activation antigen-negative cells are markedly depleted of alloreactivity. With HLA-mismatched peripheral blood mononuclear cell (PBMC) stimulators we have consistently attained (90%-95%) depletion of alloreactivity. Importantly, when purified matured monocyte-derived dendritic cells (DCs) are used as stimulators, a 100-fold (99%) reduction in alloreactivity was attained, resulting in abrogation of the secondary MLR. Significantly, the CFSEbright CD25- cells recovered from these cultures retained general immunoreactivity, including responses to Candida and cytomegalovirus (CMV) antigens. In addition, a CFSE-based approach was tested and found to be sufficient for graft-versus-host disease (GVHD) prevention in vivo, in a major histocompatibility complex (MHC) class II disparate murine model. This efficient approach to selectively deplete mature alloantigen-specific T cells may permit enhanced immune reconstitution without GVHD. (Blood. 2004;103:1158-1165)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
O. Bohana-Kashtan, S. Morisot, R. Hildreth, C. Brayton, H. I. Levitsky, and C. I. Civin
Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand
J. Immunol.,
July 1, 2009;
183(1):
696 - 705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. BIAN, Z.-K. GUO, H.-X. WANG, J.-S. WANG, H. WANG, Q.-F. LI, YUE-FENGYANG, F.-J. XIAO, C.-T. WU, and L.-S. WANG
In Vitro and In Vivo Immunosuppressive Characteristics of Hepatocyte Growth Factor-modified Murine Mesenchymal Stem Cells
In Vivo,
January 1, 2009;
23(1):
21 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Friedman, K. Goldgirsh, S. A. Berger, J. Zilberberg, J. Filicko-O'Hara, N. Flomenberg, M. Donato, S. D. Rowley, and R. Korngold
Overlap between in vitro donor antihost and in vivo posttransplantation TCR V{beta} use: a new paradigm for designer allogeneic blood and marrow transplantation
Blood,
October 15, 2008;
112(8):
3517 - 3525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Davies, J. G. Gribben, L. L. Brennan, D. Yuk, L. M. Nadler, and E. C. Guinan
Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies
Blood,
September 15, 2008;
112(6):
2232 - 2241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mielke, R. Nunes, K. Rezvani, V. S. Fellowes, A. Venne, S. R. Solomon, Y. Fan, E. Gostick, D. A. Price, C. Scotto, et al.
A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique
Blood,
April 15, 2008;
111(8):
4392 - 4402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mielke, K. Rezvani, B. N. Savani, R. Nunes, A. S. M. Yong, J. Schindler, R. Kurlander, V. Ghetie, E. J. Read, S. R. Solomon, et al.
Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease
Blood,
September 1, 2007;
110(5):
1689 - 1697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. C. Wehler, M. Nonn, B. Brandt, C. M. Britten, M. Grone, M. Todorova, I. Link, S. A. Khan, R. G. Meyer, C. Huber, et al.
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines
Blood,
January 1, 2007;
109(1):
365 - 373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Amrolia, G. Muccioli-Casadei, H. Huls, S. Adams, A. Durett, A. Gee, E. Yvon, H. Weiss, M. Cobbold, H. B. Gaspar, et al.
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation
Blood,
September 15, 2006;
108(6):
1797 - 1808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Kappel, J. Pinilla-Ibarz, A. A. Kochman, J. M. Eng, V. M. Hubbard, I. Leiner, E. G. Pamer, G. Heller, M. R. M. van den Brink, and D. A. Scheinberg
Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model
Blood,
March 1, 2006;
107(5):
2045 - 2051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R Blazar and W. J Murphy
Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD)
Phil Trans R Soc B,
September 29, 2005;
360(1461):
1747 - 1767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Solomon, S. Mielke, B. N. Savani, A. Montero, L. Wisch, R. Childs, N. Hensel, J. Schindler, V. Ghetie, S. F. Leitman, et al.
Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation
Blood,
August 1, 2005;
106(3):
1123 - 1129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. P. M. Koenen, E. Fasse, and I. Joosten
CD27/CFSE-Based Ex Vivo Selection of Highly Suppressive Alloantigen-Specific Human Regulatory T Cells
J. Immunol.,
June 15, 2005;
174(12):
7573 - 7583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Godfrey, D. J. Spoden, Y. G. Ge, S. R. Baker, B. Liu, B. L. Levine, C. H. June, B. R. Blazar, and S. B. Porter
Cord blood CD4+CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function
Blood,
January 15, 2005;
105(2):
750 - 758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Watson, G. Y. Zhang, M. Sartor, and S. I. Alexander
"Pruning" of Alloreactive CD4+ T Cells Using 5- (and 6-)Carboxyfluorescein Diacetate Succinimidyl Ester Prolongs Skin Allograft Survival
J. Immunol.,
December 1, 2004;
173(11):
6574 - 6582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Reich-Zeliger, E. Bachar-Lustig, J. Gan, and Y. Reisner
Tolerance Induction by Veto CTLs in the TCR Transgenic 2C Mouse Model. I. Relative Reactivity of Different Veto Cells
J. Immunol.,
December 1, 2004;
173(11):
6654 - 6659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. R. Martins, L. S. St. John, R. E. Champlin, E. D. Wieder, J. McMannis, J. J. Molldrem, and K. V. Komanduri
Functional assessment and specific depletion of alloreactive human T cells using flow cytometry
Blood,
December 1, 2004;
104(12):
3429 - 3436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Godfrey, Y. G. Ge, D. J. Spoden, B. L. Levine, C. H. June, B. R. Blazar, and S. B. Porter
In vitro-expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures
Blood,
July 15, 2004;
104(2):
453 - 461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
